Value your compound management team!

Abstract:

:The Discussion Forum provides a medium for airing your views on any issues related to the pharmaceutical industry and obtaining feedback and discussion on these views from others in the field. You can discuss issues that get you hot under the collar, practical problems at the bench, recently published literature, or just something bizarre or humorous that you wish to share. Publication of letters in this section is subject to editorial discretion and company-promotional letters will be rejected immediately. Furthermore, the views provided are those of the authors and are not intended to represent the views of the companies they work for. Moreover, these views do not reflect those of Elsevier, Drug Discovery Today or its editorial team. Please submit all letters to Rebecca Lawrence, News & Features Editor, Drug Discovery Today, e-mail: Rebecca.Lawrence@current-trends.com

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Ray BJ

doi

10.1016/s1359-6446(01)01816-5

subject

Has Abstract

pub_date

2001-06-01 00:00:00

pages

563

issue

11

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(01)01816-5

journal_volume

6

pub_type

杂志文章
  • CNS organoids: an innovative tool for neurological disease modeling and drug neurotoxicity screening.

    abstract::The paradigm of central nervous system (CNS) drug discovery has mostly relied on traditional approaches of rodent models or cell-based in vitro models. Owing to the issues of species differences between humans and rodents, it is difficult to correlate the robustness of data for neurodevelopmental studies. With advance...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.11.010

    authors: Chhibber T,Bagchi S,Lahooti B,Verma A,Al-Ahmad A,Paul MK,Pendyala G,Jayant RD

    更新日期:2020-02-01 00:00:00

  • Catabolic mediators as targets for cancer cachexia.

    abstract::The cachexia syndrome, characterized by a marked weight loss, anorexia, asthenia and anaemia, is invariably associated with the growth of a tumour and leads to a malnutrition status caused by the induction of anorexia or decreased food intake. In addition, the competition for nutrients between the tumour and the host ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(03)02826-5

    authors: Argilés JM,Moore-Carrasco R,Busquets S,López-Soriano FJ

    更新日期:2003-09-15 00:00:00

  • Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats.

    abstract::In therapeutic areas aimed at developing an orally administered drug, the pharmacokinetic profile of a drug candidate after oral administration in vivo is pivotal in evaluating its success. This can be done by monitoring the plasma concentration versus time after dosing and calculating the area under the curve (AUC). ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01299-9

    authors: Cox KA,Dunn-Meynell K,Korfmacher WA,Broske L,Nomeir AA,Lin CC,Cayen MN,Barr WH

    更新日期:1999-05-01 00:00:00

  • Precision medicine in oncology drug development: a pharma perspective.

    abstract::A rapid expansion in precision medicine founded on the potential for durable clinical benefit through matching a drug to a predictive marker used to select patients has driven the development of targeted drugs with accompanied companion diagnostics for patient selection. Oncology has been at the forefront, with the im...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.10.005

    authors: Hollingsworth SJ

    更新日期:2015-12-01 00:00:00

  • In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part II: The body in a Hilbertian space.

    abstract::We have broken old surviving dogmas and concepts used in computational chemistry and created an efficient in silico ADME-T pharmacological properties modeling and prediction toolbox for any xenobiotic. With the help of an innovative and pragmatic approach combining various in silico techniques, like molecular modeling...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.01.013

    authors: Jacob A,Pratuangdejkul J,Buffet S,Launay JM,Manivet P

    更新日期:2009-04-01 00:00:00

  • Intracellular transport of nanocarriers across the intestinal epithelium.

    abstract::The intestinal epithelium is the main barrier restricting the oral delivery of low-permeability drugs. Over recent years, numerous nanocarriers have been designed to improve the efficiency of oral drug delivery. However, the intracellular processes determining the transport of nanocarriers across the intestinal epithe...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.04.007

    authors: Fan W,Xia D,Zhu Q,Hu L,Gan Y

    更新日期:2016-05-01 00:00:00

  • Indacaterol/glycopyrronium: a dual bronchodilator for COPD.

    abstract::Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). Development of IND/GLY was driven by the need to improve the...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.015

    authors: Banerji D,Fogel R,Patalano F

    更新日期:2018-01-01 00:00:00

  • Dimerization of chemokine receptors in living cells: key to receptor function and novel targets for therapy.

    abstract::Chemokine receptors control and mediate a diverse array of physiological and pathogenic processes. Many seven transmembrane (TM) G-protein-coupled receptors (GPCRs), including chemokine receptors, exist as homo- or heterodimers. Growing evidence indicates that the dimeric form is the basic functional structure of thes...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.04.004

    authors: Wang J,Norcross M

    更新日期:2008-07-01 00:00:00

  • Moving forward in clinical trials for ALS: motor neurons lead the way please.

    abstract::Amyotrophic lateral sclerosis (ALS) is one of the most complex motor neuron diseases. Even though scientific discoveries are accelerating with an unprecedented pace, to date more than 30 clinical trials have ended with failure and staggering frustration. There are too many compounds that increase life span in mice, bu...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.10.014

    authors: Genç B,Özdinler PH

    更新日期:2014-04-01 00:00:00

  • Advanced nanovehicles for cancer management.

    abstract::Over the past decade, together with the improvement of traditional cancer treatments, conveniently designed (with respect to their size, shape, main material, and coating) and specifically targeted nanovehicles have been developed. Nano-sized carriers can be functionalized to recognize key structures expressed in canc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.06.020

    authors: Saenz del Burgo L,Pedraz JL,Orive G

    更新日期:2014-10-01 00:00:00

  • Dopaminergic agents for the treatment of cocaine abuse.

    abstract::Cocaine is a major drug of abuse whose devastating effects have captured the attention of health officials and policy makers. Based upon the alarming health and crime-related costs associated with the use of this powerful reinforcing drug, immediate therapies are needed for the treatment of cocaine addiction. In this ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01332-x

    authors: Smith MP,Hoepping A,Johnson KM,Trzcinska M,Kozikowski AP

    更新日期:1999-07-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)02006-2

    authors: Westwell AD

    更新日期:2001-11-15 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • PLK1 as an oncology target: current status and future potential.

    abstract::The Polo-like kinases (PLKs) have been investigated as oncology targets for several years; however, only recently have potent inhibitors been described. Here, we report on progress in the clinical validation of the PLKs as antitumor drug targets as well as recent understanding gained regarding their synergistic roles ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.05.002

    authors: McInnes C,Wyatt MD

    更新日期:2011-07-01 00:00:00

  • Recent progress toward biomarker identification in osteoarthritis.

    abstract::Osteoarthritis (OA), the most common and disabling form of arthritic disease, is characterized by a slow and progressive degeneration of articular cartilage. Its etiology is multifactorial and includes genetic predisposition, obesity and aging. In addition to the cartilage itself, OA also involves the surrounding tiss...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.01.004

    authors: De Ceuninck F,Sabatini M,Pastoureau P

    更新日期:2011-05-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01674-3

    authors: Barrett D,Barlocco D,Tranter D

    更新日期:2001-03-01 00:00:00

  • Ultrasound and transdermal drug delivery.

    abstract::Transdermal drug delivery offers an attractive alternative to the conventional drug delivery methods of oral administration and injection. However, the stratum corneum acts as a barrier that limits the penetration of substances through the skin. Application of ultrasound to the skin increases its permeability (sonopho...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(04)03170-8

    authors: Lavon I,Kost J

    更新日期:2004-08-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01910-9

    authors: Barlocco D

    更新日期:2001-08-15 00:00:00

  • Docking optimization, variance and promiscuity for large-scale drug-like chemical space using high performance computing architectures.

    abstract::There is a continuing need to hasten and improve protein-ligand docking to facilitate the next generation of drug discovery. As the drug-like chemical space reaches into the billions of molecules, increasingly powerful computer systems are required to probe, as well as tackle, the software engineering challenges neede...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.06.023

    authors: Trager RE,Giblock P,Soltani S,Upadhyay AA,Rekapalli B,Peterson YK

    更新日期:2016-10-01 00:00:00

  • Bugs, drugs, and cancer: can the microbiome be a potential therapeutic target for cancer management?

    abstract::Outnumbering our own cells over ten times, gut microbes can even be considered an additional organ. Several studies have explored the association between microbiomes and antitumor drug response. It has been reported that the presence of specific bacteria might modulate cancer progression and the efficacy of anticancer...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.02.009

    authors: Chen B,Du G,Guo J,Zhang Y

    更新日期:2019-04-01 00:00:00

  • Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

    abstract::This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.09.003

    authors: van Rijt SH,Sadler PJ

    更新日期:2009-12-01 00:00:00

  • Revival of the regulatory T cell: new targets for drug development.

    abstract::Compelling new evidence supports the idea that regulatory T cells play a major role in our immune system. Several subsets of these regulators have been identified recently. Differences in the phenotypical and functional characteristics of these subsets have immunological implications. From our growing knowledge of the...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(03)03021-6

    authors: Sutmuller RP,Offringa R,Melief CJ

    更新日期:2004-04-01 00:00:00

  • Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems.

    abstract::Psoriasis is a chronic autoimmune skin disorder triggered by either genetic factors, environmental factors, life style, or a combination thereof. Clinical investigations have identified pathogenesis, such as T cell and cytokine-mediated, genetic disposition, antimicrobial peptides, lipocalin-2, galectin-3, vaspin, fra...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.09.023

    authors: Rapalli VK,Waghule T,Gorantla S,Dubey SK,Saha RN,Singhvi G

    更新日期:2020-12-01 00:00:00

  • 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments.

    abstract::Gene expression microarrays have been used widely to address increasingly complex biological questions and to produce an unprecedented amount of data, but have yet to realize their full potential. The interpretation of microarray data remains a major challenge because of the complexity of the underlying biological net...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03565-8

    authors: Imbeaud S,Auffray C

    更新日期:2005-09-01 00:00:00

  • Critical considerations for developing nucleic acid macromolecule based drug products.

    abstract::Protein expression therapy using nucleic acid macromolecules (NAMs) as a new paradigm in medicine has recently gained immense therapeutic potential. With the advancement of nonviral delivery it has been possible to target NAMs against cancer, immunodeficiency and infectious diseases. Owing to the complex and fragile s...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.11.012

    authors: Muralidhara BK,Baid R,Bishop SM,Huang M,Wang W,Nema S

    更新日期:2016-03-01 00:00:00

  • Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses.

    abstract::Patients can mount sustained immune responses to protein therapeutics with the production of neutralizing antibodies (NAbs) that can compromise efficacy or safety of these drugs. Dendritic cells (DCs) are required for immunoglobulin (Ig) isotype switching and the production of IgG, a process involving presentation of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.06.005

    authors: Barbosa MD,Celis E

    更新日期:2007-08-01 00:00:00

  • Four disruptive strategies for removing drug discovery bottlenecks.

    abstract::Drug discovery is shifting focus from industry to outside partners and, in the process, creating new bottlenecks. Technologies like high throughput screening (HTS) have moved to a larger number of academic and institutional laboratories in the USA, with little coordination or consideration of the outputs and creating ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2012.10.007

    authors: Ekins S,Waller CL,Bradley MP,Clark AM,Williams AJ

    更新日期:2013-03-01 00:00:00

  • Recent computational advances in the identification of allosteric sites in proteins.

    abstract::Allosteric modulators have the potential to fine-tune protein functional activity. Therefore, the targeting of allosteric sites, as a strategy in drug design, is gaining increasing attention. Currently, it is not trivial to find and characterize new allosteric sites by experimental approaches. Alternatively, computati...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.07.012

    authors: Lu S,Huang W,Zhang J

    更新日期:2014-10-01 00:00:00

  • Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.

    abstract::The US Food and Drug Administration (FDA) Expanded Access (EA) Program, which allows for compassionate uses of unapproved therapeutics and diagnostics outside of clinical trials, has gained significant traction during the Coronavirus 2019 (COVID-19) pandemic. While development of vaccines has been the major focus, unc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.11.025

    authors: Rizk JG,Forthal DN,Kalantar-Zadeh K,Mehra MR,Lavie CJ,Rizk Y,Pfeiffer JP,Lewin JC

    更新日期:2020-11-27 00:00:00

  • Driving external chemistry optimization via operations management principles.

    abstract::Confronted with the need to significantly raise the productivity of remotely located chemistry CROs Pfizer embraced a commitment to continuous improvement which leveraged the tools from both Lean Six Sigma and queue management theory to deliver positive measurable outcomes. During 2012 cycle times were reduced by 48% ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.07.017

    authors: Bi FC,Frost HN,Ling X,Perry DA,Sakata SK,Bailey S,Fobian YM,Sloan L,Wood A

    更新日期:2014-03-01 00:00:00